DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Rating of “Reduce” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been assigned an average recommendation of “Reduce” from the six research firms that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has issued a buy recommendation on the company.

Several equities analysts have recently commented on DSRLF shares. Zacks Research lowered shares of DiaSorin from a “hold” rating to a “strong sell” rating in a report on Thursday, August 6th. UBS Group lowered DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. BNP Paribas Exane lowered DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Piper Sandler started coverage on DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of DiaSorin in a report on Tuesday, August 4th.

DiaSorin Price Performance

DSRLF stock opened at $86.00 on Friday. The business has a fifty day moving average of $80.42 and a two-hundred day moving average of $76.72. DiaSorin has a 52-week low of $66.50 and a 52-week high of $100.00.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.